EDITOR'S DESK

  • 4 Takeaways From The World Biosimilar Congress
    4 Takeaways From The World Biosimilar Congress

    Throughout this whirlwind two-day event, the panelists addressed the challenges of patient education and uptake, the pharmacovigilance of biosimilars, and how to navigate varying regulatory requirements in the global market. But there were four key messages relayed throughout this conference that are worth noting.

Navigating Brazil’s Emerging Biosimilar Market

The Latin American markets, and especially Brazil, hold great promise for biosimilar development, PlantForm CEO Don Stewart says. In recent years, many partnerships have been launched in Brazil between local and international companies to bolster the country’s biosimilar development. However, there are a number of things companies looking to forge joint ventures in Brazil need to keep in mind for success.

Some Biopharma Haven’t Caught Outsourcing Enthusiasm

I often write – and you read – about those individuals at biopharma companies openly enthusiastic about outsourcing. Not too long ago, though, I ran into a person who seemed to outdo the others in absolute embrace of this model. But here’s the catch: Her company won’t allow her enthusiasm to be shared “on the record.”

“Growing” Biosimilars: How Plants Bolster Manufacturing Efficiency

Roughly 15 to 20 years ago, a number of pharmaceutical companies raised money to employ tobacco technology in drug development. Unfortunately, this rush did not lead to the success many were hoping for. However, the successes of recent players in this space suggest pharma could be entering a new age in plant-based manufacturing.

Will Medicare Part D Make Biosimilar Manufacturers Pay?

Despite biosimilars’ reputation as cheaper alternatives to costly biologics, Medicare Part D patients likely won’t see great savings at least not right away. According to a recent Avelare Health report, there are two ways patients could see reduced biosimilar out-of-pocket costs. But one of these solutions could place a big burden on biosimilar manufacturers. 

More From Editor's Desk

GUEST CONTRIBUTORS

More From Guest Contributors...

BIOPROCESSING WHITE PAPERS

Examining Rescue Studies

The purpose of this whitepaper is to define a Rescue Study, outline the basic assumptions, including risks, in setting up such a trial based on DATATRAK’s prior experiences, and present the actions that can help avoid or mitigate these risks during a deployment.

Strategies For Gamma Sterilization Of Pharmaceuticals

A crucial step in pharmaceutical production is sterilization. There are many sterilization methods to choose from, such as steam, sterile filtration, ethylene oxide gas (EtO), electron beam (E-beam), and gamma radiation. Each technique has aspects that make it suitable or unsuitable for the sterilization of a particular product. By Ruth Garcia, Betty Howard, Rose LaRue, Glenn Parton, and John Walker, Steris Isomedix Services

More White Papers...

BIO INDUSTRY POSTERS

More Bioprocessing Posters...

ON-DEMAND WEBINARS

More Webinars On-Demand...